Evidence map›Paper›PMID 34548411›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19.

Magda Lourda, Majda Dzidic, Laura Hertwig, Helena Bergsten, Laura M Palma Medina, Indranil Sinha, Egle Kvedaraite, Puran Chen, Jagadeeswara R Muvva, Jean-Baptiste Gorin and 28 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 89 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Cytosolic proliferating cell nuclear antigen (PCNA) orchestrates neutrophil hyperactivation in COVID-19.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 2 institutions in 1 country.

Magda LourdaCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden; magdalini.lourda@ki.se.ORCID 0000-0003-3155-1123
Majda DzidicCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Laura HertwigCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0002-1170-0948
Helena BergstenCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Laura M Palma MedinaCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Indranil SinhaChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, 171 77, Stockholm, Sweden.ORCID 0000-0002-2513-5927
Egle KvedaraiteCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Puran ChenCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0002-2890-0022
Jagadeeswara R MuvvaCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Jean-Baptiste GorinCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Martin CornilletCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0001-7981-0927
Johanna EmgårdCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Kirsten MollCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Marina GarcíaCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0002-9130-3933
Kimia T MalekiCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0001-5382-5477
Jonas KlingströmCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0001-9076-1441
Jakob MichaëlssonCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Malin Flodström-TullbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Susanna BrighentiCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Marcus BuggertCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0003-0633-1719
Jenny MjösbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Karl-Johan MalmbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Johan K SandbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0002-6275-0750
Jan-Inge HenterChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, 171 77, Stockholm, Sweden.ORCID 0000-0002-0629-2126
Elin FolkessonDepartment of Infectious Diseases, Karolinska University Hospital, 171 77, Stockholm, Sweden.
Sara Gredmark-RussCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0002-2446-4323
Anders SönnerborgDepartment of Infectious Diseases, Karolinska University Hospital, 171 77, Stockholm, Sweden.
Lars I ErikssonDepartment of Physiology and Pharmacology, Section for Anesthesiology and Intensive Care, Karolinska Institutet, 171 77, Stockholm, Sweden.
Olav RooyackersFunction Perioperative Medicine and Intensive Care, Karolinska University Hospital, 171 77, Stockholm, Sweden.
Soo AlemanDepartment of Infectious Diseases, Karolinska University Hospital, 171 77, Stockholm, Sweden.ORCID 0000-0003-0461-4870
Kristoffer StrålinDepartment of Infectious Diseases, Karolinska University Hospital, 171 77, Stockholm, Sweden.ORCID 0000-0002-8801-3169
Hans-Gustaf LjunggrenCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0003-0908-7387
Niklas K BjörkströmCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0002-0967-076X
Mattias SvenssonCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0003-1695-7934
Andrea PonzettaCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0003-3224-802X
Anna Norrby-TeglundCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0001-9372-1795
Benedict J ChambersCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.ORCID 0000-0003-0437-8441
Karolinska KI/K COVID-19 Study Group
Karolinska University Hospital · SEKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the outset of the COVID-19 pandemic, increasing evidence suggests that the innate immune responses play an important role in the disease development. A dysregulated inflammatory state has been proposed as a key driver of clinical complications in COVID-19, with a potential detrimental role of granulocytes. However, a comprehensive phenotypic description of circulating granulocytes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients is lacking. In this study, we used high-dimensional flow cytometry for granulocyte immunophenotyping in peripheral blood collected from COVID-19 patients during acute and convalescent phases. Severe COVID-19 was associated with increased levels of both mature and immature neutrophils, and decreased counts of eosinophils and basophils. Distinct immunotypes were evident in COVID-19 patients, with altered expression of several receptors involved in activation, adhesion, and migration of granulocytes (e.g., CD62L, CD11a/b, CD69, CD63, CXCR4). Paired sampling revealed recovery and phenotypic restoration of the granulocytic signature in the convalescent phase. The identified granulocyte immunotypes correlated with distinct sets of soluble inflammatory markers, supporting pathophysiologic relevance. Furthermore, clinical features, including multiorgan dysfunction and respiratory function, could be predicted using combined laboratory measurements and immunophenotyping. This study provides a comprehensive granulocyte characterization in COVID-19 and reveals specific immunotypes with potential predictive value for key clinical features associated with COVID-19.

Indexed as

COVID-19GranulocytesHumansImmunity, InnateImmunophenotypingLeukocyte CountLungModels, BiologicalOrgan Dysfunction ScoresSARS-CoV-2Severity of Illness IndexCOVID-19eosinophil and basophil activationhigh-dimensional flow cytometryneutrophil heterogeneityviral immune responses

Identifiers

PMID34548411
PMCPMC8501786
OpenAlexW3201448114

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.